For families facing the devastating diagnosis of a high-risk brain tumour in their child, the options for treatment have often been heartbreakingly limited. Traditional therapies such as chemotherapy and radiation, while sometimes effective, often fail to fully control aggressive cancers such as medulloblastoma and high-grade glioma. These tumours can resist treatment or recur after an initial period of remission, leaving few options for parents desperate to save their children. However, recent advancements in immunotherapy, particularly CAR-T cell therapy, are offering new hope in this battle.
What is CAR-T Cell Therapy?
CAR-T cell therapy is a type of immunotherapy that represents one of the most significant breakthroughs in cancer treatment in recent years. The process involves collecting T cells—a type of immune cell—from the patient’s blood, genetically engineering them to express receptors on their surface that specifically recognise cancer cells, and then reintroducing them into the patient’s body. These modified T cells are designed to seek out and destroy cancer cells while leaving healthy cells unharmed.
Originally developed to treat certain types of blood cancers, CAR-T cell therapy has shown remarkable success, leading to complete remission in many cases where other treatments had failed. Researchers are now adapting this technology to target solid tumours, including brain tumours, where the challenges are more significant due to the difficulty of delivering the therapy across the blood-brain barrier and the complex environment of the tumour.
Adapting CAR-T Cell Therapy for
Brain Tumours
The application of CAR-T cell therapy to paediatric brain tumours has been a focus of intense research at institutions such as the UCL Great Ormond Street Institute of Child Health. Researchers are working to adapt CAR-T cells to recognise and attack specific proteins expressed on the surface of brain tumour cells. One such target is the protein GD2, which is highly expressed on certain paediatric brain tumours, including diffuse intrinsic pontine glioma (DIPG) and neuroblastoma.
By engineering CAR-T cells to specifically recognise GD2, researchers hope to create a therapy that can effectively target and kill these tumour cells while sparing healthy brain tissue. This approach has already shown promise in early clinical trials, where some patients have experienced significant tumour shrinkage and prolonged periods of remission. These trials are among the first to demonstrate the potential of CAR-T cell therapy in treating solid tumours, offering a new line of defence against paediatric brain cancers that have been resistant to other forms of treatment.
Overcoming Challenges:
The Blood-Brain Barrier and Tumour Microenvironment
One of the major challenges in treating brain tumours with CAR-T cell therapy is the blood-brain barrier, a protective layer that shields the brain from harmful substances but also prevents many therapeutic agents from reaching the brain. To address this challenge, researchers are exploring various strategies to enhance the ability of CAR-T cells to penetrate this barrier.
One promising approach involves modifying CAR-T cells to express enzymes that break down the extracellular matrix—a dense network of proteins that surrounds tumour cells and can prevent therapeutic agents from reaching their target. By disrupting this matrix, the CAR-T cells can more easily reach and infiltrate the tumour. Additionally, researchers are exploring the use of nanoparticles as delivery vehicles that can ferry CAR-T cells across the blood-brain barrier directly to the tumour site, bypassing the barrier altogether.
These strategies are still in the experimental stages, but early results are promising. The ability to successfully deliver CAR-T cells to the brain could revolutionise the treatment of high-risk paediatric brain tutors, particularly those that are resistant to conventional therapies.
The Future of CAR-T Cell Therapy in Paediatric Oncology
The future of CAR-T cell therapy in paediatric oncology looks incredibly promising. As researchers continue to refine the technology and overcome the challenges associated with treating solid tumours, we can expect to see this therapy become more widely available for children with high-risk brain tumours. The potential for CAR-T cell therapy to be combined with other forms of immunotherapy, such as checkpoint inhibitors, could further enhance its effectiveness, providing a multi-faceted approach to treating these aggressive cancers.
Additionally, as our understanding of the genetic and molecular underpinnings of paediatric brain tumours grows, CAR-T cell therapy is likely to become even more personalised. By tailoring the therapy to the specific genetic profile of each patient’s tumour, clinicians can maximise the chances of success while minimising the risk of side effects.
In the coming years, we may also see the development of “off-the-shelf” CAR-T cells—pre-engineered cells that can be used to treat multiple patients without the need for custom engineering. This could make CAR-T cell therapy more accessible and affordable, bringing its benefits to a larger number of children.
At Joss Searchlight, we are committed to advancing research into CAR-T cell therapy and other innovative treatments for paediatric brain tumours. Our support for research is driven by our mission to give every child with brain cancer the best possible chance of survival. By funding cutting-edge research and advocating for increased access to new therapies, we are helping to bring the promise of CAR-T cell therapy closer to reality for children who need it most.In addition to funding research, Joss Searchlight also works to support families affected by paediatric brain tumours. We provide information, resources, and emotional support to help families navigate the challenges of a brain tumour diagnosis. We also advocate for policies that ensure all children have access to the most advanced and effective treatments, regardless of their financial situation or where they live.
By supporting our work, you are helping to ensure that children with high-risk brain tumours have access to the best possible care. Please consider making a donation today. Your generosity will help us continue to fund vital research, support families, and advocate for better treatments for all children with brain cancer.
Help us find a cure for rare brain tumours and give support today
